Pediatric Obesity

Metabolic Diseases
2
Pipeline Programs
2
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
PANTOPRAZOLE SODIUMApproved
pantoprazole
Unknown Company
oral2016

Competitive Landscape

2 companies ranked by most advanced pipeline stage

City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
1
PantoprazolePhase 4Small Molecule1 trial
Care team informedN/A1 trial
Active Trials
NCT04364282CompletedEst. Mar 2025
NCT04248335CompletedEst. Dec 2024
35Pharma
35PharmaQC - Montreal
1 program
DEF-EI : Energy restriction induced energy deficitN/A1 trial
Active Trials
NCT03466359UnknownEst. Dec 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
City TherapeuticsPantoprazole
City TherapeuticsCare team informed
35PharmaDEF-EI : Energy restriction induced energy deficit

Clinical Trials (3)

Effect of Obesity on Proton Pump Inhibitors

Start: Jul 2018Est. completion: Dec 2024
Phase 4Completed

Stay In Treatment for Pediatric Weight Management

Start: Jul 2020Est. completion: Mar 2025
N/ACompleted
NCT0346635935PharmaDEF-EI : Energy restriction induced energy deficit

Energy Intake and Energy Deficit in Obese Adolescents

Start: Jan 2018Est. completion: Dec 2018
N/AUnknown

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space